I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
AMD and Cataract Surgery: What Patients Need to Know
How AMD and Cataracts Affect Vision Together
AMD and cataracts impair vision through two entirely different mechanisms. When both are present, understanding how each condition is contributing to your visual difficulty is the first and most important step in determining whether surgery is likely to help.
A cataract is a clouding of the natural lens inside the eye. As the lens becomes less transparent, it scatters and dims light, making images appear blurry, hazy, or washed out. AMD, by contrast, is a disease of the macula (the central portion of the retina at the back of the eye) that gradually impairs the ability to see fine detail. Tasks such as reading, recognizing faces, and driving all rely on this central vision.
When both conditions exist together, the cataract limits the amount and quality of light reaching the retina, while AMD limits how well the retina can process the light that does arrive. This layered effect often results in vision that is more impaired than either condition would cause on its own.
Your eye care providers use several tools to estimate how much of your vision loss is coming from the cataract versus from AMD. This distinction shapes what benefit you can realistically expect from surgery.
- Optical coherence tomography (OCT), which produces detailed cross-sectional images of the macula, reveals the extent of retinal damage from AMD
- A dilated eye examination evaluates the density and location of the cataract
- A potential acuity test or similar assessment may help estimate how well the retina might function if the cataract were removed
Patients whose vision loss is driven mainly by the cataract tend to experience the most meaningful improvement after surgery. Those with significant retinal damage from AMD may experience more limited gains, even when the surgery itself goes perfectly.
What Cataract Surgery Can Achieve When You Have AMD
Most AMD patients do benefit from cataract surgery, but the degree of improvement varies with the severity of the macular disease. Understanding this range of outcomes before surgery helps set expectations that are both honest and encouraging.
Research shows that the majority of AMD patients, including those with neovascular lesions, geographic atrophy, or macular scarring, experience meaningful visual improvement after cataract surgery. Patients with earlier stages of AMD, such as intermediate AMD characterized by drusen (small deposits that form beneath the retina), tend to see the greatest gains, sometimes improving by two or more lines on a standard vision chart.
Patients with more advanced macular disease may experience smaller improvements in overall sharpness but can still benefit from better contrast sensitivity, brighter color perception, and improved overall image clarity. Even modest gains in these areas often translate to meaningful improvements in daily activities and quality of life.
Cataract surgery replaces the cloudy natural lens with a clear artificial implant, restoring the optical quality of the eye. It does not, however, treat or reverse AMD. If the macula has sustained significant damage, the retina's ability to form a clear image remains limited regardless of how clear the new lens is.
Before surgery, your retina specialist and cataract surgeon will review your imaging together and discuss the likely range of visual improvement based on your macula's current condition and the density of your cataract. This conversation is one of the most valuable steps in the entire process, and we encourage patients to ask as many questions as they need during that visit.
How the Type of AMD Shapes Your Surgical Plan
AMD is not a single, uniform disease. The category and severity of your macular disease directly influence when surgery should happen, how it should be coordinated with ongoing retina care, and what to anticipate during recovery and beyond.
Patients with dry AMD, the most common form, generally have the most favorable conditions for cataract surgery. Dry AMD is characterized by drusen and gradual pigment changes in the retina. During early and intermediate stages, the macular structure is relatively intact, which means the visual gain from removing a significant cataract can be substantial.
There are no special timing restrictions tied to the macular disease at these stages. Surgery is typically scheduled once the cataract is causing enough visual impairment to justify the procedure. Monitoring for AMD continues as usual after surgery, because cataract removal does not alter the underlying course of the macular disease.
Geographic atrophy (GA) is an advanced form of dry AMD in which patches of retinal tissue have been permanently lost. Cataract surgery can still provide benefit for patients with GA, but outcomes depend largely on the size and location of the atrophic areas relative to the fovea (the very center of the macula, responsible for the sharpest central vision).
When the fovea is spared and surrounding tissue remains functional, cataract surgery may significantly improve central acuity. When atrophy involves the fovea directly, central vision improvement is more limited. However, patients may still experience better peripheral vision, improved contrast, and brighter overall perception. OCT imaging helps evaluate the remaining foveal tissue before surgery and provides a realistic picture of expected outcomes.
Wet AMD, also called neovascular AMD, occurs when abnormal blood vessels grow beneath the retina and can leak fluid or blood, causing rapid and potentially severe vision loss. Cataract surgery in this group requires careful timing and close coordination between the cataract surgeon and the retina specialist.
In general, wet AMD should be well controlled before proceeding with elective cataract surgery. Stabilizing the disease with anti-VEGF injections (medications that block abnormal blood vessel growth) for a sufficient period before surgery is associated with better long-term visual outcomes. After surgery, anti-VEGF treatment continues at the same or a similarly adjusted frequency, and careful monitoring for any change in disease activity during the postoperative period is especially important in this group.
Choosing the Right Lens Implant for AMD
The artificial lens placed inside the eye during cataract surgery, called an intraocular lens (IOL), plays a central role in surgical planning for AMD patients. The optical design of the lens has a direct and meaningful impact on the visual quality you can realistically achieve after the procedure.
A monofocal IOL focuses at a single distance, most commonly set for clear distance vision, with reading glasses used for close tasks. This design sends all incoming light to a single focal point, delivering the maximum amount and quality of light to the macula.
For patients with AMD, where the macula is already working under compromised conditions, this concentrated light delivery matters significantly. Monofocal IOLs are the lens type most widely recommended for patients with macular disease, and most cataract surgeons will explain this preference as part of the surgical consultation.
Multifocal IOLs split incoming light across multiple focal points to reduce dependence on glasses for both near and distance vision. While this technology works well for many patients with healthy retinas, it is generally not recommended for patients with AMD.
The light-splitting design reduces contrast sensitivity and overall image brightness at each focal distance. For a macula that is already functioning at a reduced level due to AMD, this additional reduction in light and contrast can worsen visual quality rather than improve it. Your surgical team will explain this tradeoff clearly and help you understand why a single-focus lens typically serves patients with macular disease better.
Some IOLs include a yellow-tinted filter that blocks certain blue wavelengths of light, in addition to the ultraviolet protection that is standard in all modern implant lenses. There has been ongoing interest in whether this filtering might benefit AMD patients, since laboratory studies have suggested that high-energy blue light may contribute to retinal oxidative stress.
However, clinical studies have not confirmed that blue-light filtering IOLs meaningfully slow AMD progression or reduce the need for future treatment. The decision about whether to use a blue-light filtering lens is typically guided by surgeon preference and the specific optical characteristics of the lens being considered, rather than a proven protective effect on the course of AMD.
Ongoing research and device development continues to explore IOL technologies designed specifically for patients with significant macular disease. Some lens designs aim to enlarge the retinal image slightly, potentially helping patients with central blind spots use adjacent functional areas of the retina more effectively. Implantable miniature telescope devices are another category that has been studied in patients with advanced AMD and substantial central vision loss.
These specialized options are not appropriate for all patients and are considered only in specific clinical circumstances. If any of these technologies might be relevant to your individual situation, your eye care team will bring them into your surgical planning discussion.
Coordinating Care Between Your Specialists
When you have both AMD and cataracts, your retina specialist and cataract surgeon work together as a team. Thoughtful communication between both providers, before and after surgery, leads to better outcomes and a smoother overall experience.
Prior to cataract surgery, your retina specialist will assess the current status of your macular disease and confirm that any active wet AMD is under good control. Imaging studies, including OCT, are typically reviewed to evaluate the condition of the macula and help estimate the likely benefit of surgery.
If you are receiving anti-VEGF injections on a regular schedule, your retina specialist and cataract surgeon will coordinate the timing of your injection appointments around your surgical date. This coordination ensures continuity of AMD treatment without unnecessary gaps or scheduling conflicts.
Following cataract surgery, your retina specialist continues monitoring your AMD on the same schedule as before. For patients with wet AMD, closer observation for signs of renewed disease activity in the weeks after surgery is particularly important, since any intraocular procedure can involve a temporary inflammatory response that may affect the retina.
AMD management does not pause during cataract surgery recovery. Injections, supplements, and monitoring appointments continue on their established schedule, with any necessary timing adjustments coordinated by your care team well in advance.
Frequently Asked Questions
Here are answers to questions we commonly hear from patients who are considering cataract surgery while managing AMD.
This concern is understandable and has been studied in large-scale research, including data from the Age-Related Eye Disease Study 2 (AREDS2). Those studies found no increased risk of progressing to late-stage AMD as a direct result of cataract surgery. Some earlier population studies suggested a possible link, but separating the effects of surgery from the natural progression of AMD in the same aging population is methodologically difficult. The current body of evidence does not support avoiding medically necessary cataract surgery out of concern for AMD acceleration. Routine retinal monitoring after surgery remains important, not because surgery increases risk, but because AMD follows its own course regardless of any other procedure.
In most cases, elective cataract surgery is postponed until wet AMD has been stabilized through anti-VEGF treatment. Proceeding while the disease is actively leaking or worsening can make outcomes less predictable and may complicate the postoperative period. If your cataract is causing significant, urgent visual impairment that cannot reasonably wait, your care team will weigh the specific risks and benefits for your individual situation and make a recommendation accordingly. This is not a blanket prohibition but a guiding principle that gets applied based on each patient's circumstances.
Timing depends on three main factors considered together: how much the cataract is limiting your vision and daily function, how stable your AMD currently is, and what your personal vision goals are. For dry or intermediate AMD, timing is largely driven by the impact of the cataract itself. For wet AMD, disease stability takes priority. Your retina specialist and cataract surgeon coordinate this decision as a shared plan rather than two separate choices made in isolation. Being specific about which daily activities have become most difficult helps your team prioritize appropriately.
Yes, without exception. Cataract surgery addresses the lens-related component of your vision loss and does not alter the biology of AMD or reduce the need for ongoing management. If you were receiving anti-VEGF injections before surgery, you will continue receiving them afterward on the same or a comparably adjusted schedule. AREDS2 nutritional supplements, if recommended by your retina specialist, should continue without interruption through surgery and recovery. The two treatments serve entirely different purposes and do not substitute for each other in any way.
Often, yes, and this is a benefit that many patients do not anticipate. A dense cataract can significantly degrade the quality of OCT images and other retinal scans, making it harder to assess subtle changes in the macula precisely. Once the cataract is replaced with a clear IOL, imaging quality frequently improves, sometimes substantially. This enhanced visibility can allow your retina specialist to monitor AMD activity with greater accuracy, detect early signs of disease progression more reliably, and make more confident decisions about treatment timing. It is one of the indirect but genuinely meaningful benefits of cataract surgery for AMD patients.
Expert Retina Care Across Connecticut
At New England Retina Associates, our fellowship-trained vitreoretinal surgeons collaborate closely with cataract surgeons and referring providers throughout Connecticut to ensure every patient with AMD receives coordinated, expert care at each step of the surgical process. If you have been diagnosed with both AMD and cataracts and would like a thorough evaluation of your options, we welcome you to schedule a consultation at any of our four office locations.
30 Years of Care & Commitment
